E3 Ligand-linker Conjugate 5

<strong>E3 Ligand-linker Conjugate 5</strong>_x000D_ <strong>Catalog number:</strong> B2012901_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 315.4 g/mol_x000D_ <strong>Supplied as:</strong> Lyophilized Powder_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> E3 Ligand linker Conjugate 5_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Sosič I, Bricelj A, Steinebach C. E3 ligase ligand chemistries: from building blocks to protein degraders Chem Soc Rev. 2022 May 10;51(9):3487-3534._x000D_ 2: Bricelj A, Steinebach C, Kuchta R, Gütschow M, Sosič I. E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points Front Chem. 2021 Jul 5;9:707317._x000D_ 3: Wang C, Zhang Y, Wu Y, Xing D. Developments of CRBN-based PROTACs as potential therapeutic agents Eur J Med Chem. 2021 Dec 5;225:113749._x000D_ 4: Khan S, He Y, Zhang X, Yuan Y, Pu S, Kong Q, Zheng G, Zhou D. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics Oncogene. 2020 Jun;39(26):4909-4924._x000D_ 5: Scheepstra M, Hekking KFW, van Hijfte L, Folmer RHA. Bivalent Ligands for Protein Degradation in Drug Discovery Comput Struct Biotechnol J. 2019 Jan 25;17:160-176._x000D_ 6: Nieto-Jiménez C, Morafraile EC, Alonso-Moreno C, Ocaña A. Clinical considerations for the design of PROTACs in cancer Mol Cancer. 2022 Mar 7;21(1):67._x000D_ 7: Weng G, Shen C, Cao D, Gao J, Dong X, He Q, Yang B, Li D, Wu J, Hou T. PROTAC-DB: an online database of PROTACs Nucleic Acids Res. 2021 Jan 8;49(D1):D1381-D1387._x000D_ 8: Konstantinidou M, Li J, Zhang B, Wang Z, Shaabani S, Ter Brake F, Essa K, Dömling A. PROTACs- a game-changing technology Expert Opin Drug Discov. 2019 Dec;14(12):1255-1268._x000D_ 9: Guenette RG, Yang SW, Min J, Pei B, Potts PR. Target and tissue selectivity of PROTAC degraders Chem Soc Rev. 2022 Jul 18;51(14):5740-5756._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/34951318">10: Fischer F, Alves Avelar LA, Murray L, Kurz T. Designing HDAC-PROTACs: lessons learned so far Future Med Chem. 2022 Jan;14(3):143-166. </a>_x000D_ _x000D_ <strong>Products Related to E3 Ligand-linker Conjugate 5 can be found at</strong> <a href="https://moleculardepot.com/product-category/Chemicals/"> Chemicals</a>